Altay Therapeutics Inc., based in San Carlos, operates in the biotechnology sector, focusing on the development of innovative drug therapies. The company is strategically located near renowned research institutions such as Stanford University and the University of California San Francisco, which enhances its access to cutting-edge scientific resources and collaborations.

Altay Therapeutics specializes in targeting transcription factors, which are proteins that control the expression of multiple genes. Misregulation of these transcription factors can lead to various diseases. The company employs an integrated approach to drug development, combining biochemical assays, computational biology, and chemoproteomics. This multidisciplinary strategy allows Altay to identify and develop small molecule inhibitors that can effectively target and modulate transcription factors.

The company's primary market includes patients suffering from diseases caused by the misregulation of transcription factors, such as facioscapulohumeral muscular dystrophy (FSHD). By inhibiting the DUX4 transcription factor, Altay aims to prevent muscle cell death in FSHD patients, thereby improving their quality of life.

Altay Therapeutics operates on a business-to-business (B2B) model, collaborating with pharmaceutical companies and research institutions. The company generates revenue through research grants, partnerships, and licensing agreements. Notably, Altay was accepted into Y Combinator's Winter 2020 batch and received a Golden Ticket from Bristol Myers Squibb, highlighting its potential and credibility in the biotech industry.

In summary, Altay Therapeutics is a biotech company dedicated to developing therapies for diseases caused by transcription factor misregulation. It leverages advanced scientific techniques and strategic partnerships to bring innovative treatments to market.

Keywords: biotechnology, drug development, transcription factors, FSHD, small molecule inhibitors, computational biology, chemoproteomics, Y Combinator, Bristol Myers Squibb, research collaborations.